Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

Business Of Biotech

We love to hear from our listeners. Send us a message.

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, and building therapeutic franchise "skyscrapers." Tangular also shares his thoughts on commercializing RNAi therapies for larger patient populations, compared with rare disease populations, and reflects on changes in the biopharmaceutical sales and promotion model.
This episode is brought to you by Avantor. For more information, visit avantorsciences.com

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Introduction to Alnylam and Tolga Tangular (00:00:00)

2. Career Journey in Pharmaceutical Commercialization (00:06:23)

3. RNAi Therapeutics: Advantages and Opportunities (00:11:45)

4. Solving Medication Compliance Challenges (00:17:03)

5. Global Expansion Strategy (00:23:04)

6. Value-Based Contracting Approach (00:31:00)

7. Rare Disease Diagnosis and Market Evolution (00:42:50)

8. Top Priorities and Future Direction (00:51:03)